IDH1 inhibitorFDA-approvedInvestigational
Ivosidenib
How it works
Blocks the IDH1 enzyme, which is overactive in AML cells, disrupting cancer cell growth and survival signals.
Cancer types
Leukemia— IDH1-mutated AML
Efficacy
In clinical trials, around 40% of AML patients achieved a complete or partial response, with a median progression-free survival of approximately 5 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Gilteritinib with Ivosidenib or Enasidenib for Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Testing Ivosidenib as Maintenance Therapy After AML Transplant | Leukemia | phase-2 | — | Source → |
| Testing CPX-351 and Ivosidenib for IDH1 Mutated Blood Cancers | Leukemia | phase-2 | — | Source → |
| Testing Ivosidenib as Maintenance Therapy for Certain Blood Cancers | Leukemia | phase-2 | — | Source → |
| New Study Examines Ivosidenib and Azacitidine for AML Patients | Leukemia | phase-3 | — | Source → |
| Testing Ivosidenib and Venetoclax for IDH1 Mutated Hematologic Malignancies | Leukemia | phase-1 | — | Source → |
| New Study Compares Effectiveness of Two Leukemia Treatments | Leukemia | phase-3 | Treatment with OLU versus IVO was associated with significantly higher rates of complete response (RD: 0.25; 95%CI: 0.01, 0.49), transfusion independence (RD: 0.27; 95%CI: 0.01, 0.53), and OS (HR: 0.33; 95%CI: 0.11, 0.94). | Source → |
| New Study Compares Effectiveness of Leukemia Treatments | Leukemia | meta-analysis | — | Source → |
| Lab Study Reveals How Cancer Drug Works at the Molecular Level | Leukemia | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.